Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement

Sattler S, Forlini C, Racine É, Sauer C (2013)
PLoS ONE 8(8): e71452.

Zeitschriftenaufsatz | Veröffentlicht | Englisch
 
Download
OA
Autor*in
Sattler, SebastianUniBi; Forlini, Cynthia; Racine, Éric; Sauer, CarstenUniBi
Abstract / Bemerkung
Enhancing cognitive performance with substances–especially prescription drugs–is a fiercely debated topic among scholars and in the media. The empirical basis for these discussions is limited, given that the actual nature of factors that influence the acceptability of and willingness to use cognitive enhancement substances remains unclear. In an online factorial survey, contextual and substance-specific characteristics of substances that improve academic performance were varied experimentally and presented to respondents. Students in four German universities rated their willingness to use and moral acceptance of different substances for cognitive enhancement. We found that the overall willingness to use performance enhancing substances is low. Most respondents considered the use of these substances as morally unacceptable. Situational influences such as peer pressure, policies concerning substance use, relative performance level of peers, but also characteristics of the substance, such as perceptions of substance safety, shape the willingness and acceptability of using a substance to enhance academic performance. Among the findings is evidence of a contagion effect meaning that the willingness was higher when the respondents have more CE drug users in their social network. We also found deterrence effects from strong side effects of using the substance, as well as from policy regulations and sanctions. Regulations might activate social norms against usage and sanctions can be seen as costly to users. Moreover, enhancement substances seem to be most tempting to low performers to catch up with others compared to high performers. By identifying contextual factors and substance characteristics influencing the willingness and acceptability of cognitive enhancers, policy approaches could consider these insights to better manage the use of such substances.
Erscheinungsjahr
2013
Zeitschriftentitel
PLoS ONE
Band
8
Ausgabe
8
Art.-Nr.
e71452
ISSN
1932-6203
eISSN
1932-6203
Page URI
https://pub.uni-bielefeld.de/record/2614390

Zitieren

Sattler S, Forlini C, Racine É, Sauer C. Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE. 2013;8(8): e71452.
Sattler, S., Forlini, C., Racine, É., & Sauer, C. (2013). Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE, 8(8), e71452. doi:10.1371/journal.pone.0071452
Sattler, S., Forlini, C., Racine, É., and Sauer, C. (2013). Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE 8:e71452.
Sattler, S., et al., 2013. Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE, 8(8): e71452.
S. Sattler, et al., “Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement”, PLoS ONE, vol. 8, 2013, : e71452.
Sattler, S., Forlini, C., Racine, É., Sauer, C.: Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement. PLoS ONE. 8, : e71452 (2013).
Sattler, Sebastian, Forlini, Cynthia, Racine, Éric, and Sauer, Carsten. “Impact of Contextual Factors and Substance Characteristics on Perspectives toward Cognitive Enhancement”. PLoS ONE 8.8 (2013): e71452.
Alle Dateien verfügbar unter der/den folgenden Lizenz(en):
Copyright Statement:
This Item is protected by copyright and/or related rights. [...]
Volltext(e)
Access Level
OA Open Access
Zuletzt Hochgeladen
2019-09-06T09:18:17Z
MD5 Prüfsumme
fe920f45052d53f5181817d2531c261a

Link(s) zu Volltext(en)
Access Level
Restricted Closed Access

15 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Bottom Up Ethics - Neuroenhancement in Education and Employment.
Bard I, Gaskell G, Allansdottir A, da Cunha RV, Eduard P, Hampel J, Hildt E, Hofmaier C, Kronberger N, Laursen S, Meijknecht A, Nordal S, Quintanilha A, Revuelta G, Saladié N, Sándor J, Santos JB, Seyringer S, Singh I, Somsen H, Toonders W, Torgersen H, Torre V, Varju M, Zwart H., Neuroethics 11(3), 2018
PMID: 30220937
Deciphering moral intuition: How agents, deeds, and consequences influence moral judgment.
Dubljević V, Sattler S, Racine E., PLoS One 13(10), 2018
PMID: 30273370
Use and Propensity to Use Substances as Cognitive Enhancers in Italian Medical Students.
Pighi M, Pontoni G, Sinisi A, Ferrari S, Mattei G, Pingani L, Simoni E, Galeazzi GM., Brain Sci 8(11), 2018
PMID: 30423911
Towards a Moral Ecology of Pharmacological Cognitive Enhancement in British Universities.
Vagwala MK, Bicquelet A, Didziokaite G, Coomber R, Corrigan O, Singh I., Neuroethics 10(3), 2017
PMID: 28890739
The is and ought of the Ethics of Neuroenhancement: Mind the Gap.
Forlini C, Hall W., Front Psychol 6(), 2015
PMID: 26779100
Attitudes toward pharmacological cognitive enhancement-a review.
Schelle KJ, Faulmüller N, Caviola L, Hewstone M., Front Syst Neurosci 8(), 2014
PMID: 24860438

87 References

Daten bereitgestellt von Europe PubMed Central.

Cognitive enhancement: methods, ethics, regulatory challenges.
Bostrom N, Sandberg A., Sci Eng Ethics 15(3), 2009
PMID: 19543814
Psychopharmacological enhancment
AUTHOR UNKNOWN, 2008
Feeling 'better than well'.
Hall W., EMBO Rep. 5(12), 2004
PMID: 15577921
Neuroenhancement: status quo and perspectives.
Normann C, Berger M., Eur Arch Psychiatry Clin Neurosci 258 Suppl 5(), 2008
PMID: 18985306
Developing public health approaches to cognitive enhancement: an analysis of current reports
AUTHOR UNKNOWN, 2011
Professor's little helper.
Sahakian B, Morein-Zamir S., Nature 450(7173), 2007
PMID: 18097378
Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany.
Franke AG, Christmann M, Bonertz C, Fellgiebel A, Huss M, Lieb K., Pharmacopsychiatry 44(7), 2011
PMID: 21993866
Cognitive Enhancement, Lifestyle Choice or Misuse of Prescription Drugs?
AUTHOR UNKNOWN, 2010
Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences.
Mache S, Eickenhorst P, Vitzthum K, Klapp BF, Groneberg DA., Wien Med Wochenschr 162(11-12), 2012
PMID: 22707077

AUTHOR UNKNOWN, 0
Towards responsible use of cognitive-enhancing drugs by the healthy.
Greely H, Sahakian B, Harris J, Kessler RC, Gazzaniga M, Campbell P, Farah MJ., Nature 456(7223), 2008
PMID: 19060880
Effects of modafinil on dopamine and dopamine transporters in the male human brain
AUTHOR UNKNOWN, 2009

AUTHOR UNKNOWN, 0
Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students.
Dietz P, Striegel H, Franke AG, Lieb K, Simon P, Ulrich R., Pharmacotherapy 33(1), 2013
PMID: 23307544
Use of cognitive enhancement medication among northern Italian university students.
Castaldi S, Gelatti U, Orizio G, Hartung U, Moreno-Londono AM, Nobile M, Schulz PJ., J Addict Med 6(2), 2012
PMID: 22456492
The promise and predicament of cosmetic neurology.
Chatterjee A., J Med Ethics 32(2), 2006
PMID: 16446417
Neurocognitive enhancement: what can we do and what should we do?
AUTHOR UNKNOWN, 2004
The likelihood of cognitive enhancement
AUTHOR UNKNOWN, 2011
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review.
Repantis D, Schlattmann P, Laisney O, Heuser I., Pharmacol. Res. 62(3), 2010
PMID: 20416377
Antidepressants for neuroenhancement in healthy individuals: a systematic review
AUTHOR UNKNOWN, 2008
Methylphenidate facilitates learning-induced amygdala plasticity.
Tye KM, Tye LD, Cone JJ, Hekkelman EF, Janak PH, Bonci A., Nat. Neurosci. 13(4), 2010
PMID: 20208527
Cognitive enhancement by drugs in health and disease.
Husain M, Mehta MA., Trends Cogn. Sci. (Regul. Ed.) 15(1), 2010
PMID: 21146447
Poll results: look who's doping.
Maher B., Nature 452(7188), 2008
PMID: 18401370
Weak evidence for large claims contribute to the phantom debate
AUTHOR UNKNOWN, 2010
Ethical considerations in the framing of the cognitive enhancement debate
AUTHOR UNKNOWN, 2012
Expectations regarding cognitive enhancement create substantial challenges.
Racine E, Forlini C., J Med Ethics 35(8), 2009
PMID: 19644002
On the argument that enhancement is "cheating".
Schermer M., J Med Ethics 34(2), 2008
PMID: 18234944
The nonmedical use of prescription ADHD medications: results from a national Internet panel.
Novak SP, Kroutil LA, Williams RL, Van Brunt DL., Subst Abuse Treat Prev Policy 2(), 2007
PMID: 17974020
Nonmedical prescription stimulant use among a sample of college students: relationship with psychological variables.
Weyandt LL, Janusis G, Wilson KG, Verdi G, Paquin G, Lopes J, Varejao M, Dussault C., J Atten Disord 13(3), 2009
PMID: 19767596
Risk and protective factors for nonmedical use of prescription stimulants and methamphetamine among adolescents.
Herman-Stahl MA, Krebs CP, Kroutil LA, Heller DC., J Adolesc Health 39(3), 2006
PMID: 16919799
Attitudes toward cognitive enhancement in users and nonusers of stimulants for cognitive enhancement: a pilot study
AUTHOR UNKNOWN, 2012
Perceived risk and use as predictors of substance use among college students
AUTHOR UNKNOWN, 1995
Motives and perceived consequences of nonmedical ADHD medication use by college students: are students treating themselves for attention problems?
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS., J Atten Disord 13(3), 2008
PMID: 18664714

AUTHOR UNKNOWN, 0
Multiple surveys of students and survey fatigue
AUTHOR UNKNOWN, 2004
Influence of preliminary contact on mail returns
AUTHOR UNKNOWN, 1966
Incentives in web surveys: methodological issues and a review
AUTHOR UNKNOWN, 2006
Factorial survey methods for studying beliefs and judgments
AUTHOR UNKNOWN, 2006
Judgments of the fairness of using performance enhancing drugs.
Sabini J, Monterosso J., Ethics Behav 15(1), 2005
PMID: 16127858
25 years of factorial surveys in sociology: a review
AUTHOR UNKNOWN, 2009
Who should get what? Fairness judgments of the distribution of earnings
AUTHOR UNKNOWN, 1978
Der faktorielle Survey und die Messung von Normen
AUTHOR UNKNOWN, 2001
The vagaries of the vignette world. A comment on Alves and Rossi
AUTHOR UNKNOWN, 1980
Rejoinder to Faia
AUTHOR UNKNOWN, 1980
The Vignette Technique in Survey Research
AUTHOR UNKNOWN, 1987
Ephedrine use is risky business.
Landry GL., Curr Sports Med Rep 2(1), 2003
PMID: 12831669
Ephedrine's deadly edge.
Turk MP., US News World Rep 123(1), 1997
PMID: 10168348
The federal ban on ephedrine dietary supplements. an important event for pain practitioners and patients
AUTHOR UNKNOWN, 2004
Over-the-counter stimulants: abuse and addiction.
Tinsley JA, Watkins DD., Mayo Clin. Proc. 73(10), 1998
PMID: 9787749
Energy drinks and caffeine-related adverse effects.
Sepkowitz KA., JAMA 309(3), 2013
PMID: 23330171
The use of vignettes in survey research
AUTHOR UNKNOWN, 1978
An examination of the effects of social desirability bias on business ethics: research results
AUTHOR UNKNOWN, 2002
Designing vignette studies in marketing
AUTHOR UNKNOWN, 2002

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Deflating the neuroenhancement bubble
AUTHOR UNKNOWN, 2011
Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee.
Larriviere D, Williams MA, Rizzo M, Bonnie RJ; AAN Ethics, Law and Humanities Committee, Williams MA, Larriviere D, Gordon J, Bernat JL, Evans P, Haberfeld E, Jacobson PL, King DW, McGuire D, Reimschisel T, Rizzo M, Snyder RD, Sagsveen MG, Hutchins JC, Kasmirski KM., Neurology 73(17), 2009
PMID: 19776378

AUTHOR UNKNOWN, 0
Smart drugs "as common as coffee": media hype about neuroenhancement.
Partridge BJ, Bell SK, Lucke JC, Yeates S, Hall WD., PLoS ONE 6(11), 2011
PMID: 22140584

AUTHOR UNKNOWN, 0
Time to address stimulant abuse on our campuses.
Rosenfield D, Hebert PC, Stanbrook MB, Flegel K, MacDonald NE., CMAJ 183(12), 2011
PMID: 21896701
Autonomy and coercion in academic “cognitive enhancement” using methylphenidate: perspectives of a pragmatic study of key stakeholders
AUTHOR UNKNOWN, 2009
Commercializing cognitive neurotechnology--the ethical terrain.
Eaton ML, Illes J., Nat. Biotechnol. 25(4), 2007
PMID: 17420741
Risk and rationality in adolescent decision making: implications for theory, practice, and public policy
AUTHOR UNKNOWN, 2006

AUTHOR UNKNOWN, 0
Using social networks to understand and prevent substance use: a transdisciplinary perspective.
Valente TW, Gallaher P, Mouttapa M., Subst Use Misuse 39(10-12), 2004
PMID: 15587948

AUTHOR UNKNOWN, 0
Predicting dishonest actions using the theory of planned behavior
AUTHOR UNKNOWN, 1991
The interplay of moral norms and instrumental incentives in crime causation
AUTHOR UNKNOWN, 2010
Expected utility, self-control, morality, and criminal probability
AUTHOR UNKNOWN, 2010
Overcorrecting the neuroenhancement discussion.
Farah MJ., Addiction 106(6), 2011
PMID: 21564378
Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S., J Am Acad Child Adolesc Psychiatry 47(1), 2008
PMID: 18174822
University students' perceptions of the learning environment and academic outcomes: implications for theory and practice
AUTHOR UNKNOWN, 2002
Approaches to teaching design subjects: a quantitative analysis
AUTHOR UNKNOWN, 2002
The Impact of Anonymity on Responses to Sensitive Questions
AUTHOR UNKNOWN, 2000
Sensitive questions in surveys.
Tourangeau R, Yan T., Psychol Bull 133(5), 2007
PMID: 17723033

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Web of Science

Dieser Datensatz im Web of Science®

Quellen

PMID: 23940757
PubMed | Europe PMC

Suchen in

Google Scholar